Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

A New Generation Screening Collection (AXXDIV2.0) is Now Available for Drug Discovery Programs

Published: Thursday, September 26, 2013
Last Updated: Thursday, September 26, 2013
Bookmark and Share
Axxam S.p.A. announced that an entirely new generation screening collection is now available for drug discovery programs: AXXDIV2.0 made up with 240,000 carefully selected small molecules.

The selection of the compounds was carried out building on Axxam’s broad screening expertise and significant input was given by the Company’s team of medicinal and computational chemists to ensure that the identified screening hits may represent promising and favorable starting points for further optimization.

In order to meet the manifold needs of customers, the new screening collection AXXDIV2.0 includes three different subsets: Explorer Set (providing a scaffold based approach), Probe Set (ensuring highest chemical diversity), and Discovery Set (covering the fragment-like space). Enamine (www.enamine.net) was chosen as the compounds supplier having one of the world’s largest, most diverse and novel screening collection. Through Axxam`s partnership with Enamine, building blocks for all the compounds can be provided to allow significant speed up of the hit expansion and optimization processes.

Dr. Doris Hafenbradl, VP Discovery Services, Axxam, said: “Key for any successful hit discovery program is the quality of the compound library. That’s why we put a major effort into assembling this compound collection and applied the most stringent filters to favor lead-like properties. With this new collection we are addressing the needs of our clients to provide novel chemistry combined with a flexible model of generating custom subsets. The feedback from our customers has been extremely positive.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Axxam Awarded by Lombardy Region
Company awarded with EUR 0.5 million to support a innovative high throughput method for early “in vitro” safety risk assessment of compounds.
Saturday, October 29, 2011
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!